Introduction
In western populations, mitral regurgitation (MR) is the second most common valvular heart disorder, after aortic stenosis, with a reported prevalence of approximately 2%. This prevalence increases with age and affects up to 10% of those over the age of 75.1,2 Severe MR tends to run an insidious yet malignant course and, without intervention, confers a poor prognosis. Untreated, it is associated with progressive left ventricular remodelling, and ultimately dysfunction, resulting in increased morbidity and an annual mortality rate of 5%.3-5
Mitral valve surgery (MVS), typically mitral valve repair (MVr), for severe degenerative MR